Home

Richard W Pascoe

CIK 1343266 · Chief Executive Officer · last filed 2024-01-08

Richard W Pascoe is a Chief Executive Officer who has filed 65 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for SEEL, was dated Jan 8, 2024. Across all open-market trades the lifetime net is −$703.6K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $375.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$375.3K

Companies

7

Total Filings

65

Lifetime Open-Market Net

-$703.6K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SEELOS THERAPEUTICS, INC. (SEEL) Delisted Director 40 $0.39 $16 $0 7 2024-01-08
ZVRA Chief Executive Officer 29,973 $12.52 $375.3K $42.0K 1 2023-03-13
ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Chief Executive Officer 19,973 $5.81 $116.0K $94.5K 16 2023-01-13
Histogen Inc. (HSTO) Delisted President, CEO & Director 1,500 $0.21 $322 $35.2K 4 2021-03-30
SEELOS THERAPEUTICS, INC. (APRI) Delisted CEO & Secretary 6,674 — — $128.1K 14 2018-11-30
Pernix Sleep, Inc. (SOMX) Delisted President and CEO 104,927 — — -$1.00M 19 2013-01-03
ARIAD PHARMACEUTICALS INC (ARIA) Delisted Senior VP, COO — — — $0 3 2008-04-15

Recent Filings

65 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-08 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2023-03-13 ZVRA Buy (P) +10,000 $42.0K EDGAR
2023-01-13 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +9,500 $51.7K EDGAR
2023-01-11 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
2023-01-05 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2022-05-18 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +5,000 $24.6K EDGAR
2022-02-03 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
2022-01-06 SEELOS THERAPEUTICS, INC. (SEEL) Delisted Grant (A) — $0 EDGAR
2021-11-30 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Buy (P) +1,500 $11.8K EDGAR
2021-11-10 ZEVRA THERAPEUTICS, INC. (KMPH) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 65
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.